Prevalence of Hypogonadism Among Males with Type 2 Diabetes Mellitus in a Malaysian Tertiary Hospital:
A Cross-Sectional Study
DOI:
https://doi.org/10.15605/jafes.040.02.11Keywords:
hypogonadism, type 2 diabetes mellitus, testosterone, prevalenceAbstract
Objective. Previous studies have indicated that clinical hypogonadism is common among males with type 2 diabetes mellitus (T2DM). However, the reported prevalence varies due to the diverse diagnostic criteria used in these studies. This study aims to determine the prevalence of clinical hypogonadism among Malaysian T2DM males and their associated factors.
Methodology. A total of 360 participants who fulfilled the inclusion criteria were included in this study. Their socio-demographic and clinical parameters were documented and a total testosterone level was sampled from a morning fasting serum. Patients with serum total testosterone of 8-12 nmol/L had their serum total testosterone repeated and their symptoms assessed with the Aging Male Symptoms (AMS) scale. Clinical hypogonadism was diagnosed with total testosterone <12 nmol/L and cfT <0.255 nmol/L, in addition to an AMS score of >26.
Results. The prevalence of clinical hypogonadism among Malaysian T2DM males was 17.5% (n = 63), with 55.6% of them having hypogonadotropic hypogonadism. There is a significant association between clinical hypogonadism with waist circumference >94 cm (p <0.001), obesity (p <0.001), hypertension (p = 0.010), coronary artery disease (p = 0.014) and peripheral artery disease (p = 0.022). There is a significant difference in the weight (p = 0.001), BMI (p <0.001), waist circumference P <0.001), serum HDL-C levels (p <0.001), serum triglycerides levels (p = 0.001) and serum TyG index (p <0.001). Diabetic males with increasing age (adjusted OR = 1.070, 95% CI 1.004-1.146, p = 0.038), presence of coronary artery diseases (adjusted OR = 2.08, 95% CI 1.220-10.219, p = 0.020) and low total testosterone (adjusted OR = 2.451, 95% CI 1.908-3.155, p <0.001) are at higher risk of developing clinical hypogonadism.
Conclusion. This study is the first in the Asian region to use stricter criteria for diagnosing hypogonadism. Despite these stringent criteria, the prevalence of hypogonadism remains significantly high among Malaysian T2DM males. It is particularly common in diabetic males over 35 years old with coronary artery disease, regardless of A1c control and the duration of diabetes.
Downloads
References
1. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462–8. https://pubmed.ncbi.nlm.nih.gov/15531498 https://doi.org/10.1210/jc.2004-0804 DOI: https://doi.org/10.1210/jc.2004-0804
2. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–7. https://pubmed.ncbi.nlm.nih.gov/17392552 https://doi.org/10.2337/dc06-1426 DOI: https://doi.org/10.2337/dc06-1426
3. Li Y, Zhang M, Liu X, et al. Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. Andrology. 2017;5(4):739–43. https://pubmed.ncbi.nlm.nih.gov/28470687 https://doi.org/10.1111/andr.12360 DOI: https://doi.org/10.1111/andr.12360
4. Liu RT, Chung MS, Wang PW, et al. The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes. Urology. 2013;82(1):124–9. https://pubmed.ncbi.nlm.nih.gov/23676359 https://doi.org/10.1016/j.urology.2013.03.023 DOI: https://doi.org/10.1016/j.urology.2013.03.023
5. Ho CH, Jaw FS, Wu CC, et al. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men. J Sex Med. 2015;12(2):389–97. https://pubmed.ncbi.nlm.nih.gov/25441980 https://doi.org/10.1111/jsm.12777 DOI: https://doi.org/10.1111/jsm.12777
6. Mattack N. The evaluation of serum levels of testosterone in type 2 diabetic men and its relation with lipid profile. J Clin Diagn Res. 2015;9(1):BC04–7. https://pubmed.ncbi.nlm.nih.gov/25737972 https://pmc.ncbi.nlm.nih.gov/articles/PMC4347063 https://doi.org/10.7860/JCDR/2015/11049.5381 DOI: https://doi.org/10.7860/JCDR/2015/11049.5381
7. Zheng R, Cao L, Cao W, et al. Risk factors for hypogonadism in male patients with type 2 diabetes. J Diabetes Res. 2016;2016:5162167. https://pubmed.ncbi.nlm.nih.gov/27006953 https://pmc.ncbi.nlm.nih.gov/articles/PMC4781970 https://doi.org/10.1155/2016/5162167 DOI: https://doi.org/10.1155/2016/5162167
8. Hamilton EJ, Davis WA, Makepeace A, et al. Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: The Fremantle Diabetes Study Phase II. Clin Endocrinol (Oxf). 2016;85(3):444–52. https://pubmed.ncbi.nlm.nih.gov/27106511 https://doi.org/10.1111/cen.13087 DOI: https://doi.org/10.1111/cen.13087
9. Ganesh HK, Sarathi HAV, George J, et al. Prevalence of hypogonadism in patients with type 2 diabetes mellitus in an Asian Indian study group. Endocr Pract. 2009;15(6):513–20. https://pubmed.ncbi.nlm.nih.gov/19454386 https://doi.org/10.4158/EP09035.ORR DOI: https://doi.org/10.4158/EP09035.ORR
10. Cheung KKT, Lau ESH, So WY, et al. Low testosterone and clinical outcomes in Chinese men with type 2 diabetes mellitus – Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2017;123:97–105. https://pubmed.ncbi.nlm.nih.gov/27997863 https://doi.org/10.1016/j.diabres.2016.11.012 DOI: https://doi.org/10.1016/j.diabres.2016.11.012
11. Charan S, Garg S, Chander R, et al. To study the relationship between serum testosterone, hsCRP and carotid atherosclerosis in men from Northwest Punjab with type 2 diabetes mellitus. J Evol Med Dent Sci. 2017;6(23):1872–6. DOI: https://doi.org/10.14260/Jemds/2017/411
12. Madhu S, Aslam M, Aiman A, Siddiqui A, Dwivedi S. Prevalence of hypogonadism in male type 2 diabetes mellitus patients with and without coronary artery disease. Indian J Endocrinol Metab 2017;21(1):31–7. https://pubmed.ncbi.nlm.nih.gov/28217495 https://pmc.ncbi.nlm.nih.gov/articles/PMC5240077 https://doi.org/10.4103/2230-8210.195999 DOI: https://doi.org/10.4103/2230-8210.195999
13. Agarwal P, Singh P, Chowdhury S, , et al. Prevalence of hypogonadism in Indian males with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21(1):64–70. https://pubmed.ncbi.nlm.nih.gov/28217500 https://pmc.ncbi.nlm.nih.gov/articles/PMC5240083 https://doi.org/10.4103/2230-8210.196008 DOI: https://doi.org/10.4103/2230-8210.196008
14. Herrero A, Marcos M, Galindo P, Miralles JM, Corrales JJ. Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. Andrology. 2018;6(1):58–63. https://pubmed.ncbi.nlm.nih.gov/29145714 https://doi.org/10.1111/andr.12433
15. Anupam B, Shivaprasad C, Vijaya S, Sridevi A, Aiswarya Y, Nikhil K. Prevalence of hypogonadism in patients with type 2 diabetes mellitus among the Indian population. Diabetes Metab Syndr. 2020;14(5):1299–304. https://pubmed.ncbi.nlm.nih.gov/32755825 https://doi.org/10.1016/j.dsx.2020.07.006 DOI: https://doi.org/10.1016/j.dsx.2020.07.006
16. Ahmad S, Jerampang P, Tohid H, Ali MF, Jamil TR, Kong CHC. Testosterone deficiency syndrome among males with type 2 diabetes mellitus in East Malaysia. Nagoya J Med Sci. 2020;82(4):613–21. https://pubmed.ncbi.nlm.nih.gov/33311792 https://pmc.ncbi.nlm.nih.gov/articles/PMC7719445 https://doi.org/10.18999/nagjms.82.4.613
17. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96(9):2643–51. https://pubmed.ncbi.nlm.nih.gov/21896895 https://pmc.ncbi.nlm.nih.gov/articles/PMC3167667 https://doi.org/10.1210/jc.2010-2724 DOI: https://doi.org/10.1210/jc.2010-2724
18. Kumari N, Khan A, Shaikh U, et al. Comparison of testosterone levels in patients with and without type 2 diabetes. Cureus. 2021;13(7):e16288. https://pubmed.ncbi.nlm.nih.gov/34381648 https://pmc.ncbi.nlm.nih.gov/articles/PMC8350217 https://doi.org/10.7759/cureus.16288 DOI: https://doi.org/10.7759/cureus.16288
19. Zhou Y, Tian R, Wang X, Sun J, Zhu L, An X. Occurrence of hypogonadotropic hypogonadism in Chinese men with type 2 diabetes. Clin Endocrinol (Oxf). 2022;96(6):837–46. https://pubmed.ncbi.nlm.nih.gov/35075664 https://doi.org/10.1111/cen.14680 DOI: https://doi.org/10.1111/cen.14680
20. Singh J, Sahoo AK, Swain J, Mangaraj S, Kanwar JB, Manglunia A. Assessment of hypogonadism and its determinants among adult men with type 2 diabetes mellitus. Prim Care Diabetes. 2023;17(4):348–53. https://pubmed.ncbi.nlm.nih.gov/37188551 https://doi.org/10.1016/j.pcd.2023.05.005 DOI: https://doi.org/10.1016/j.pcd.2023.05.005
21. Waddankeri SS, Waddankeri M, Arora K, Mangshetty BG. Androgen Deficiency in Aging Males (ADAM) score as a predictor of total testosterone levels in type 2 diabetes mellitus: A prospective, cross-sectional study. J Assoc Physicians India. 2024;72(4):31–7. https://pubmed.ncbi.nlm.nih.gov/38881081 https://doi.org/10.59556/japi.72.0514 DOI: https://doi.org/10.59556/japi.72.0514
22. Kang W, Mohamad Sithik MN, Khoo J, Ooi Y, Lim Q, Lim L. Gaps in the management of diabetes in Asia: A need for improved awareness and strategies in men’s sexual health. J Diabetes Investig. 2022;13(12):1945–57. https://pubmed.ncbi.nlm.nih.gov/36151988 https://pmc.ncbi.nlm.nih.gov/articles/PMC9720202 https://doi.org/10.1111/jdi.13903 DOI: https://doi.org/10.1111/jdi.13903
23. Oguz A, Sahin M, Ulgen C, Uyan M, Gul K. Overt hypogonadism is a cardiovascular risk factor in type 2 diabetic males: An observational study. Andrologia. 2022;54(1):e14271. https://pubmed.ncbi.nlm.nih.gov/34632609 https://doi.org/10.1111/and.14271 DOI: https://doi.org/10.1111/and.14271
24. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33. https://pubmed.ncbi.nlm.nih.gov/23999642 https://doi.org/10.1530/EJE-13-0321 DOI: https://doi.org/10.1530/EJE-13-0321
25. Sharma R, Oni OA, Gupta K, et al. Normalisation of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706–15. https://pubmed.ncbi.nlm.nih.gov/26248567 https://doi.org/10.1093/eurheartj/ehv346 DOI: https://doi.org/10.1093/eurheartj/ehv346
26. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012;14(3):428–35. https://pubmed.ncbi.nlm.nih.gov/22522504 https://pmc.ncbi.nlm.nih.gov/articles/PMC3720171 https://doi.org/10.1038/aja.2012.21 DOI: https://doi.org/10.1038/aja.2012.21
27. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. Heart. 2011;97(11):870–5. https://pubmed.ncbi.nlm.nih.gov/21177660 https://doi.org/10.1136/hrt.2010.210757 DOI: https://doi.org/10.1136/hrt.2010.210757
28. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2020. Diabetes Care 2020;43(Suppl 1):S14–31. https://pubmed.ncbi.nlm.nih.gov/31862745 https://doi.org/10.2337/dc20-S002 DOI: https://doi.org/10.2337/dc20-S002
29. Wan Nazaimoon WM, Md Isa SH, Wan Mohamad WB, al. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabet Med 2013;30(7):825–8. https://pubmed.ncbi.nlm.nih.gov/23413941 https://doi.org/10.1111/dme.12161 DOI: https://doi.org/10.1111/dme.12161
30. Jayasena CN, de Silva NL, O’Reilly MW, et al. Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine. Clin Endocrinol (Oxf). 2024;101(5):531-4. https://pubmed.ncbi.nlm.nih.gov/37393195 https://doi.org/10.1111/cen.14929 DOI: https://doi.org/10.1111/cen.14929
31. Lee J, Kim B, Kim W, et al. Lipid indices as simple and clinically useful surrogate markers for insulin resistance in the U.S. population. Sci Rep. 2021;11(1):2366. https://pubmed.ncbi.nlm.nih.gov/33504930 https://pmc.ncbi.nlm.nih.gov/articles/PMC7840900 https://doi.org/10.1038/s41598-021-82053-2 DOI: https://doi.org/10.1038/s41598-021-82053-2
32. Vasques ACJ, Novaes FS, de Oliveira MdS, et al. TyG index performs better than HOMA in a Brazilian population. Diabetes Res Clin Pract. 2011;93(3):8–10. https://pubmed.ncbi.nlm.nih.gov/21665314 https://doi.org/10.1016/j.diabres.2011.05.030 DOI: https://doi.org/10.1016/j.diabres.2011.05.030
33. Moncada I. Testosterone and men’s quality of life. Aging Male. 2006;9(4):189–93. https://pubmed.ncbi.nlm.nih.gov/17178553 https://doi.org/10.1080/13685530601003180 DOI: https://doi.org/10.1080/13685530601003180
34. Tan HM, Low WY, Tong SF, et al. Aging male symptoms scale (AMS) for health-related quality of life in aging men: Translation and adaptation in Malay. Malays J Public Health Med. 2015;15(2):17–23.
35. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72. https://pubmed.ncbi.nlm.nih.gov/10523012 https://doi.org/10.1210/jcem.84.10.6079 DOI: https://doi.org/10.1210/jcem.84.10.6079
36. Kang W, Siruhan M, Shree V, Karupiah M, Sukor N, Kamaruddin N. Hypogonadal symptoms and sexual dysfunction among males with T2DM. J ASEAN Fed Endocr Soc. 2021;36(1):49. https://doi.org/10.15605/jafes.036.S68 DOI: https://doi.org/10.15605/jafes.036/S68
37. Herrero A, Marcos M, Galindo P, Miralles JM, Corrales JJ. Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. Andrology. 2018;6(1):58–63. https://pubmed.ncbi.nlm.nih.gov/29145714 https://doi.org/10.1111/andr.12433 DOI: https://doi.org/10.1111/andr.12433
38. Teka S, Kinde S, Dedefo G, Mudi K, Tarekegn G. Hypogonadism and associated risk factors in male patients with type 2 diabetes mellitus attending the diabetic clinic of Tikur Anbessa Specialized Teaching Hospital, Addis Ababa, Ethiopia. J Endocrinol Metab Diabetes South Afr. 2019;24(1):16–22. DOI: https://doi.org/10.1080/16089677.2018.1541668
39. Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): Assessment and indications for testosterone therapy. Med J Aust. 2016;205(4):173–8. https://pubmed.ncbi.nlm.nih.gov/27510348 https://doi.org/10.5694/mja16.00393 DOI: https://doi.org/10.5694/mja16.00393
40. Mohr BA, Guay AT, O’Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: Results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2005;62(1):64–73. https://pubmed.ncbi.nlm.nih.gov/15638872 https://doi.org/10.1111/j.1365-2265.2004.02174.x DOI: https://doi.org/10.1111/j.1365-2265.2004.02174.x
41. Travison TG, Shackelton R, Araujo AB, et al. The natural history of symptomatic androgen deficiency in men: Onset, progression, and spontaneous remission. J Am Geriatr Soc. 2008;56(5):831–9. https://pubmed.ncbi.nlm.nih.gov/18454749 https://pmc.ncbi.nlm.nih.gov/articles/PMC5556701 https://doi.org/10.1111/j.1532-5415.2008.01679.x DOI: https://doi.org/10.1111/j.1532-5415.2008.01679.x
42. Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf). 2007;67(6):853–62. https://pubmed.ncbi.nlm.nih.gov/18052942 https://doi.org/10.1111/j.1365-2265.2007.02976.x DOI: https://doi.org/10.1111/j.1365-2265.2007.02976.x
43. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44. https://pubmed.ncbi.nlm.nih.gov/29562364 https://doi.org/10.1210/jc.2018-00229 DOI: https://doi.org/10.1210/jc.2018-00229
44. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45(6):1211–9. https://pubmed.ncbi.nlm.nih.gov/338622 https://doi.org/10.1210/jcem-45-6-1211 DOI: https://doi.org/10.1210/jcem-45-6-1211
45. Sepu N, Adeleye JO, Kuti MO. Serum testosterone in Nigerian men with type 2 diabetes mellitus and its relationship with insulin sensitivity and glycemic control. J Natl Med Assoc. 2021;113(4):456–63. https://pubmed.ncbi.nlm.nih.gov/33353658 https://doi.org/10.1016/j.jnma.2020.11.014 DOI: https://doi.org/10.1016/j.jnma.2020.11.014
46. Melnichenko GA, Shestakova MV, Rozhivanov RV. The prevalence of hypogonadism in men with type 2 diabetes mellitus in clinical practice. Diabetes Mellitus. 2019;22(2):127–30. https://doi.org/10.14341/DM9944 DOI: https://doi.org/10.14341/DM9944
47. Dhindsa S, Reddy A, Karam JS, et al. Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease. Eur J Endocrinol. 2015;173(3):359–66. https://pubmed.ncbi.nlm.nih.gov/26101371 https://doi.org/10.1530/EJE-15-0359 DOI: https://doi.org/10.1530/EJE-15-0359
48. Rabijewski M, Papierska L, Zgliczyński W, Piątkiewicz P. The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in the Polish population. Biomed Res Int. 2013;2013:767496. https://pubmed.ncbi.nlm.nih.gov/24222915 https://pmc.ncbi.nlm.nih.gov/articles/PMC3810490 https://doi.org/10.1155/2013/767496 DOI: https://doi.org/10.1155/2013/767496
49. Cao W, Zheng RD, Xu SH, Fan YF, Sun HP, Liu C. Association between sex hormone and blood uric acid in male patients with type 2 diabetes. Int J Endocrinol. 2017;2017:4375253. https://pubmed.ncbi.nlm.nih.gov/29109738 https://pmc.ncbi.nlm.nih.gov/articles/PMC5646336 https://doi.org/10.1155/2017/4375253 DOI: https://doi.org/10.1155/2017/4375253
50. Hernández-Mijares A, García-Malpartida K, Solá-Izquierdo E, et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med. 2010;7(5):1954–64. https://pubmed.ncbi.nlm.nih.gov/20214724 https://doi.org/10.1111/j.1743-6109.2010.01705.x DOI: https://doi.org/10.1111/j.1743-6109.2010.01705.x
51. Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type 2 diabetes mellitus and stable coronary artery disease. Int J Cardiol. 2010;143(3):343–8. https://pubmed.ncbi.nlm.nih.gov/19395096 https://doi.org/10.1016/j.ijcard.2009.03.072 DOI: https://doi.org/10.1016/j.ijcard.2009.03.072
52. van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: Systematic review and meta-analysis. Eur J Endocrinol. 2020;182(1):11–21. https://pubmed.ncbi.nlm.nih.gov/31652416 https://doi.org/10.1530/EJE-19-0666 DOI: https://doi.org/10.1530/EJE-19-0666
53. Al Hayek A, Ajlouni K, Khader Y, Jafal S, Khawaja N, Robert A. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: A cross-sectional study. J Family Community Med. 2013;20(3):179–84. https://pubmed.ncbi.nlm.nih.gov/24672276 https://pmc.ncbi.nlm.nih.gov/articles/PMC3957172 https://doi.org/10.4103/2230-8229.122006 DOI: https://doi.org/10.4103/2230-8229.122006
54. Arafa M, Zohdy W, Aboulsoud S, Shamloul R. Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus. Andrologia. 2012;44(Suppl 1):756–63. https://pubmed.ncbi.nlm.nih.gov/22211848 https://doi.org/10.1111/j.1439-0272.2011.01262.x DOI: https://doi.org/10.1111/j.1439-0272.2011.01262.x
55. Bebb R, Millar A, Brock G. Sexual dysfunction and hypogonadism in men with diabetes. Can J Diabetes. 2018;42(Suppl 1): S228–33. https://pubmed.ncbi.nlm.nih.gov/29650102 https://doi.org/10.1016/j.jcjd.2017.10.035 DOI: https://doi.org/10.1016/j.jcjd.2017.10.035
56. Cai M, Cui R, Yang P, et al. Incidence and risk factors of hypogonadism in male patients with latent autoimmune diabetes and classic type 2 diabetes. Front Endocrinol (Lausanne). 2021;12:675525. https://pubmed.ncbi.nlm.nih.gov/34135863 https://pmc.ncbi.nlm.nih.gov/articles/PMC8202076 DOI: 10.3389/fendo.2021.675525 DOI: https://doi.org/10.3389/fendo.2021.675525
57. Cao W, Zheng RD, Fan YF, Liu C. Correlation between testosterone and metabolic index in male patients with type 2 diabetes mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018;49(2):235–8. https://ykxb.scu.edu.cn/en/article/id/38eddbb1-8a2d-400b-a0ae-8492dcca91ff
58. Al Hayek AA, Robert AA, Alshammari G, Hakami H, Al Dawish MA. Assessment of hypogonadism in men with type 2 diabetes: A cross-sectional study from Saudi Arabia. Clin Med Insights Endocrinol Diabetes. 2017;10. 1179551417710209. https://pubmed.ncbi.nlm.nih.gov/28579862 https://pmc.ncbi.nlm.nih.gov/articles/PMC5439570 DOI: 10.1177/1179551417710209 DOI: https://doi.org/10.1177/1179551417710209
59. Mirzaei MR, Amini M, Aminorroaya A. Prevalence of hypogonadism in diabetic men in Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran. J Res Med Sci. 2012;17(7):602–6. https://pubmed.ncbi.nlm.nih.gov/23798917 https://pmc.ncbi.nlm.nih.gov/articles/PMC3685773
60. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018;41(7):1516–25. https://pubmed.ncbi.nlm.nih.gov/29934480 https://pmc.ncbi.nlm.nih.gov/articles/PMC6014549 https://doi.org/10.2337/dc17-2510 DOI: https://doi.org/10.2337/dc17-2510
61. Bernie AM, Scovell JM, Ramasamy R. Comparison of questionnaires used for screening and symptom identification in hypogonadal men. Aging Male. 2014;17(4):195–8. https://pubmed.ncbi.nlm.nih.gov/25247629 https://doi.org/10.3109/13685538.2014.963041 DOI: https://doi.org/10.3109/13685538.2014.963041
62. Clinical Practice Guidelines Development Group. Malaysia Clinical Practice Guidelines: Management of type 2 diabetes mellitus, 6th ed. 2020. https://mems.my/cpg-management-of-type-2-diabetes-mellitus-6th-edition/
63. Ministry of Health Malaysia. National Health and Morbidity survey 2019: Non-communicable diseases, Healthcare demand and healthcare literacy. 2019. https://iptk.moh.gov.my/images/technical_report/2020/4_Infographic_Booklet_NHMS_2019_-_English.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Waye Hann Kang, Norlela Sukor, Nor Azmi Kamaruddin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
